双重血浆置换术联合补肝利脂汤治疗重度高甘油三酯血症合并非酒精性脂肪性肝病患者的疗效分析

doi:10.3760/cma.j.issn.1007-1245.2024.24.025

摘要/Abstract

摘要：

目的　探究双重血浆置换术（double filtration plasmapheresis，DFPP）联合补肝利脂汤治疗重度高甘油三酯血症合并非酒精性脂肪性肝病的临床疗效。方法　本研究为随机对照试验。选取2021年6月至2022年6月安康市中医医院收治的68例重度高甘油三酯血症合并非酒精性脂肪性肝病患者为研究对象，采用随机数字表法分为对照组与观察组，每组34例。对照组男18例，女16例，年龄（42.62±8.55）岁，采用DFPP+苯扎贝特治疗，DFPP治疗后第1天开始口服苯扎贝特，每次0.2 g，每日3次，持续治疗24周。观察组男20例，女14例，年龄（43.43±7.25）岁，采用DFPP+补肝利脂汤治疗，DFPP治疗后第1天开始口服补肝利脂汤，每次200 ml，每日1剂，饭前30 min内服用，持续治疗24周。对比治疗前后两组甘油三酯、载脂蛋白A-Ⅰ（ApoA-Ⅰ）、载脂蛋白B（ApoB）、高密度脂蛋白胆固醇（HDL-C）、低密度脂蛋白胆固醇（LDL-C）等血脂指标以及丙氨酸转氨酶（ALT）、白蛋白（ALB）、天冬氨酸转氨酶（AST）等肝功能生化指标，并比较两组肝脏影像学结果。采用χ²检验、t检验进行统计分析。结果　治疗24周后，观察组甘油三酯、LDL-C、ApoB均低于对照组［（4.13±1.09）mmol/L比（6.03±1.65）mmol/L、（3.13±0.58）mmol/L比（3.91±0.75）mmol/L、（0.76±0.23）g/L比（0.86±0.17）g/L］，HDL-C、ApoA-I均高于对照组［（1.88±0.53）mmol/L比（1.42±0.43）mmol/L、（1.81±0.39）g/L比（1.58±0.32）g/L］，差异均有统计学意义（t=5.602、4.797、2.039、3.930、2.658，均P<0.05）；观察组ALT、AST均低于对照组［（28.62±3.23）U/L比（34.32±1.68）U/L、（21.29±4.34）U/L比（35.44±5.72）U/L］，ALB高于对照组［（49.21±4.31）g/L比（45.34±4.28）g/L］，差异均有统计学意义（t=9.138、11.488、3.715，均P<0.05）；肝脏影像学检查结果显示，观察组的肝脏肋下斜径小于对照组［（9.98±3.54）cm比（12.05±4.78）cm］，差异有统计学意义（t=2.029，P=0.046）；对照组患者轻、中、重度肝脂肪浸润分别为7例（20.59%）、15例（44.12%）、12例（35.29%），观察组分别为20例（58.82%）、11例（32.35%）、3例（8.82%），差异有统计学意义（χ²=12.275，P=0.002）。结论　DFPP联合补肝利脂汤能有效改善重度高甘油三酯血症合并非酒精性脂肪性肝病患者的生化指标和肝脏功能，对肝脏影像学表现有积极影响，对重度高甘油三酯血症合并非酒精性脂肪性肝病的治疗具有潜在应用价值。

关键词:

非酒精性脂肪性肝病, 高甘油三脂血症, 重度, 双重血浆置换术, 补肝利脂汤, 肝功能, 影像学分析

Abstract:

Objective　To explore the effect of double filtration plasmapheresis (DFPP) combined with Bugan Lizhi decoction in the treatment of severe hypertriglyceridemia complicated with non-alcoholic fatty liver disease. Methods　This study was a randomized controlled trial. A total of 68 patients diagnosed with severe hypertriglyceridemia combined with non-alcoholic fatty liver disease in the Gastroenterology Department of Ankang Hospital of Traditional Chinese Medicine from June 2021 to June 2022 were selected as the study objects, and were divided into a control group and an observation group by the random number table method, with 34 cases in each group. In the control group, 18 males and 16 females, aged (42.62±8.55) years, were treated with DFPP plus oral bezafibrate: on the first day after DFPP treatment, bezafibrate 0.2 g was taken orally, 3 times a day, for 24 weeks. In the observation group, 20 males and 14 females, aged (43.43±7.25) years, were treated with DFPP + oral Bugan Lizhi decoction: the above traditional Chinese medicine was taken orally on the first day after blood purification treatment, 200 ml each time, 1 dose per day, within 30 minutes before meals, for 24 weeks. Biochemical indexes such as triglyceride, apolipoprotein A-Ⅰ (ApoA-Ⅰ), apolipoprotein B (ApoB), high density lipoprotein cholesterol (HDL-C), and low density lipoprotein cholesterol (LDL-C) and liver function biochemical indexes such as alanine aminotransferase (ALT), albumin (ALB), and aspartate aminotransferase (AST) were compared between the two groups before and after treatment. The liver function indexes and liver imaging results were compared between the two groups before and after treatment. χ² test and t test were used for statistical analysis. Results　After 24 weeks of treatment, the levels of triglyceride, LDL-C, and ApoB in the observation group were lower than those in the control group [(4.13±1.09) mmol/L vs. (6.03±1.65) mmol/L, (3.13±0.58) mmol/L vs. (3.91±0.75) mmol/L, (0.76±0.23) g/L vs. (0.86± 0.17) g/L], and the levels of HDL-C and ApoA-I were higher than those in the control group [(1.88±0.53) mmol/L vs. (1.42±0.43) mmol/L, (1.81±0.39) g/L vs. (1.58±0.32) g/L], with statistically significant differences (t=5.602, 4.797, 2.039, 3.930, and 2.658, all P<0.05). After 24 weeks of treatment, the levels of ALT and AST in the observation group were lower than those in the control group [(28.62±3.23) U/L vs. (34.32±1.68) U/L, (21.29±4.34) U/L vs. (35.44±5.72) U/L], and the level of ALB was higher than that in the control group [(49.21±4.31) g/L vs. (45.34±4.28) g/L], with statistically significant differences (t=9.138, 11.488, and 3.715, all P<0.05). The results of liver imaging examination after 24 weeks of treatment showed that the oblique diameter of liver subcostal in the observation group was smaller than that in the control group [(9.98±3.54) cm vs. (12.05±4.78) cm], with a statistically significant difference (t=2.029, P=0.046). There were 7 cases (20.59%), 15 cases (44.12%), and 12 cases (35.29%) of mild, moderate, and severe hepatic cellular fat infiltration in the control group, and 20 cases (58.82%), 11 cases (32.35%), and 3 cases (8.82%) in the observation group, with a statistically significant difference (χ²=12.275, P=0.002). Conclusion　DFPP combined with Bugan Lizhi decoction can effectively improve the biochemical indicators and liver function in severe hypertriglyceridemia complicated with non-alcoholic fatty liver disease patients, with positive effects on hepatic imaging manifestations, suggesting its potential application value in the treatment of severe hypertriglyceridemia complicated with non-alcoholic fatty liver disease.

Key words:

Non-alcoholic fatty liver disease, Hypertriglyceridemia, severe, Double filtration plasmapheresis, Bugan Lizhi decoction, Liver function, Imaging analysis

王鲜庭程贤文王新磊.

双重血浆置换术联合补肝利脂汤治疗重度高甘油三酯血症合并非酒精性脂肪性肝病患者的疗效分析 [J]. 国际医药卫生导报, 2024, 30(24): 4186-4191.

Wang Xianting, Cheng Xianwen, Wang Xinlei.

Effect analysis of double filtration plasmapheresis combined with Bugan Lizhi decoction in the treatment of severe hypertriglyceridemia complicated with non-alcoholic fatty liver disease [J]. International Medicine and Health Guidance News, 2024, 30(24): 4186-4191.

参考文献

[1] Farooqi A, Omotosho YB, Zahra F. New onset diabetes mellitus complicated by hypertriglyceridemia-induced Pancreatitis[J]. Cureus, 2021, 13(2): e13569. DOI: 10.7759/cureus.13569.
[2] 江建军. 非诺贝特治疗脂肪肝肝功能异常者高甘油三酯血症的安全性[J]. 心血管康复医学杂志,2003,12(4):340-342. DOI:10.3969/j.issn.1008-0074.2003.04.026.
[3] Gonzales KM, Donato LJ, Shah P, et al. Measurement of apolipoprotein B levels helps in the identification of patients at risk for hypertriglyceridemic pancreatitis[J]. J Clin Lipidol, 2021, 15(1): 97-103. DOI: 10.1016/j.jacl.2020.11.010.
[4] 过忆. 泽泻清脂汤治疗高甘油三脂血症60例[J]. 四川中医,2004,22(10):56. DOI:10.3969/j.issn.1000-3649.2004. 10.036.
[5] Yang AL, McNabb-Baltar J. Hypertriglyceridemia and acute pancreatitis[J]. Pancreatology, 2020, 20(5): 795-800. DOI: 10.1016/j.pan.2020.06.005.
[6] 李景旺,江军亮.中医药治疗高脂血症性脂肪肝的研究进展[J].慢性病学杂志,2006,10(S2):172-173.
[7] 李正鑫,陈洋溢,赵志敏,等. 基于肝脏病理学对慢性乙型肝炎肝硬化患者FibroTouch测量值的影响因素分析[J]. 临床肝胆病杂志,2019,35(2):338-344. DOI:10.3969/j.issn.1001-5256.2019.02.019.
[8] Hirano R, Namazuda K, Hirata N. Double filtration plasmapheresis: review of current clinical applications[J]. Ther Apher Dial, 2021, 25(2): 145-151. DOI: 10.1111/1744-9987.13548.
[9] 陈宗炳. «中国脂肪肝防治指南(科普版)»一书出版[J]. 实用肝脏病杂志,2015,18(3):248. DOI:10.3969/j.issn.1672- 5069.2015.03.008.
[10] 张符林. 高脂血症性重症急性胰腺炎患者行血浆置换术治疗的疗效分析[J]. 中国药物与临床,2022,22(4):366-369. DOI:10.11655/zgywylc2022.04.020.
[11] 董建华,黄力,李川,等. 离心/膜分离组合式双重血浆置换治疗重症狼疮性肾炎的临床研究[J]. 肾脏病与透析肾移植杂志,2021,30(4):308-314. DOI:10.3969/j.issn.1006- 298X.2021.04.002.
[12] 任迪,曾晶晶,赖锴,等. PE、DFPP治疗妊娠期高三酰甘油血症急性胰腺炎对比观察[J]. 山东医药,2020,60(3):78-81. DOI:10.3969/j.issn.1002-266X.2020.03.022.
[13] 陈锐,罗俊,周印,等. 双重血浆置换术治疗重症高脂血症性胰腺炎的疗效评价[J]. 当代医药论丛,2023,21(17):40-42. DOI:10.3969/j.issn.2095-7629.2023.17.011.
[14] 金九如. 中西医结合治疗高甘油三酯血症的临床观察[J]. 浙江临床医学,2014(11):1779-1779,1780.
[15] 安莹,王宏,闫铁静. 中药口服与保留灌肠联合生长抑素在高脂血症性重症急性胰腺炎中应用[J]. 辽宁中医杂志,2023,50(11):99-102. DOI:10.13192/j.issn.1000-1719. 2023.11.027.
[16] 彭晓林,龚秀茹,国亚新,等. 肝生化指标联合MRI同反相位对非酒精性脂肪肝脂肪定量的预测价值[J]. 肝脏,2023,28(6):711-715. DOI:10.3969/j.issn.1008-1704.2023. 06.021.
[17] 刘云霄,孙微,窦婧,等. 基于Fibrotouch探讨代谢相关脂肪性肝病与肝纤维化的相关性[J]. 海南医学院学报,2023,29(22):1710-1717. DOI:10.13210/j.cnki.jhmu. 20230811.001.
[18] 努尔吉马·阿合尼牙孜,刘一佳,梁灿灿,等. 甘油三酯葡萄糖指数与非酒精性脂肪性肝病脂肪变程度及肝纤维化的相关性研究[J]. 海南医学院学报,2023,29(23):1794-1800. DOI:10.13210/j.cnki.jhmu.20231017.002.
[19] 余林德,陈占利. 中西医治疗高脂血症临床研究进展[J]. 亚太传统医药,2014,10(22):35-38.
[20] 吴皎,涂思,张清源,等. 健脾渗湿祛痰化浊类复方治疗高脂血症的临床研究热点分析[J]. 中成药,2023,45(3):1025-1030. DOI:10.3969/j.issn.1001-1528.2023.03.059.
[21] 唐校柱,闵捷,吕昕予,等. 枸杞子功效物质的药理作用研究进展[J]. 交通医学,2023,37(4):345-348. DOI:10.19767/j.cnki.32-1412.2023.04.004.
[22] 杨静云,李宇兴,赖永勤,等. 山楂、泽泻、决明子与红曲霉混合发酵产物对高血脂大鼠调脂作用研究[J]. 中草药,2017,48(7):1369-1373. DOI:10.7501/j.issn.0253-2670. 2017.07.018.
[23] Li Y, Ji X, Wu H, et al. Mechanisms of traditional Chinese medicine in modulating gut microbiota metabolites-mediated lipid metabolism[J]. J Ethnopharmacol, 2021, 278: 114207. DOI: 10.1016/j.jep.2021.114207.
[24] Borja MS, Hammerson B, Tang C, et al. Effects of niacin and omega-3 fatty acids on HDL-apolipoprotein A-I exchange in subjects with metabolic syndrome[J]. PLoS One, 2024, 19(2): e0296052. DOI: 10.1371/journal.pone.0296052.
[25] Deb S, Puthanveetil P, Sakharkar P. A population-based cross-sectional study of the association between liver enzymes and lipid levels[J]. Int J Hepatol, 2018, 2018: 1286170. DOI: 10.1155/2018/1286170.
[26] 曾新杰,赵一帆,伍育华,等. 丹参提取物对肝纤维化小鼠治疗效果的研究分析[J].中文科技期刊数据库(全文版)自然科学,2024(1):149-152.
[27] 黄春丽,冯光维,汪巍,等. 泽泻对MSG大鼠肝损伤及抗氧化作用的影响[J]. 黔南民族医专学报,2022,35(1):4-6.
[28] 张苏兰. 515例中老年超声检查脂肪肝与肝脏体积相关性分析[J]. 吉林医学,2014,35(2):324-325.